Greg Matlashewski

12.4k total citations · 3 hit papers
161 papers, 9.8k citations indexed

About

Greg Matlashewski is a scholar working on Public Health, Environmental and Occupational Health, Epidemiology and Molecular Biology. According to data from OpenAlex, Greg Matlashewski has authored 161 papers receiving a total of 9.8k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Public Health, Environmental and Occupational Health, 90 papers in Epidemiology and 32 papers in Molecular Biology. Recurrent topics in Greg Matlashewski's work include Research on Leishmaniasis Studies (109 papers), Trypanosoma species research and implications (69 papers) and Cancer-related Molecular Pathways (19 papers). Greg Matlashewski is often cited by papers focused on Research on Leishmaniasis Studies (109 papers), Trypanosoma species research and implications (69 papers) and Cancer-related Molecular Pathways (19 papers). Greg Matlashewski collaborates with scholars based in Canada, United States and Switzerland. Greg Matlashewski's co-authors include Wen‐Wei Zhang, Lawrence Banks, L. Crawford, Hugues Charest, Miranda Thomas, Sylvie Labrecque, Ann Kalita, Anirban Ghosh, Kathryn J. Moore and Sureemas Buates and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Greg Matlashewski

161 papers receiving 9.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer

1998 797 citations Miranda Thomas, Ann Kalita et al. profile →
Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically

1999 603 citations Miranda Thomas, Ann Kalita et al. Molecular and Cellular Biology profile →
Isolation of human‐p53‐specific monoclonal antibodies and their use in the studies of human p53 expression

1986 484 citations Lawrence Banks, Greg Matlashewski et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Greg Matlashewski Canada	54	4.8k	4.3k	3.0k	2.9k	1.2k	161	9.8k
Gavin Screaton United Kingdom	55	1.5k 0.3×	4.4k 1.0×	4.6k 1.5×	842 0.3×	2.7k 2.2×	128	11.8k
Andreas Suhrbier Australia	55	1.9k 0.4×	3.9k 0.9×	2.1k 0.7×	834 0.3×	2.9k 2.4×	218	9.4k
Michel J. Tremblay Canada	52	2.0k 0.4×	1.4k 0.3×	2.5k 0.8×	521 0.2×	3.5k 2.9×	238	9.3k
Timothy F. Kowalik United States	42	2.2k 0.5×	367 0.1×	2.7k 0.9×	1.8k 0.6×	850 0.7×	84	5.6k
Ali Amara France	47	1.8k 0.4×	3.0k 0.7×	1.8k 0.6×	2.1k 0.7×	4.7k 3.9×	82	10.5k
Britta Wahrén Sweden	56	5.4k 1.1×	467 0.1×	3.1k 1.0×	1.8k 0.6×	4.5k 3.7×	491	13.7k
Brett D. Lindenbach United States	40	4.7k 1.0×	2.1k 0.5×	2.7k 0.9×	399 0.1×	1.3k 1.0×	71	10.5k
Dirk P. Dittmer United States	55	3.4k 0.7×	362 0.1×	3.1k 1.0×	5.9k 2.1×	1.9k 1.6×	232	9.8k
Paul M. Kaye United Kingdom	55	4.0k 0.8×	5.9k 1.4×	1.0k 0.3×	370 0.1×	3.6k 3.0×	195	9.4k
Sujan Shresta United States	49	1.5k 0.3×	5.0k 1.2×	1.7k 0.6×	632 0.2×	2.5k 2.0×	104	8.8k

Countries citing papers authored by Greg Matlashewski

Since Specialization

Citations

This map shows the geographic impact of Greg Matlashewski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg Matlashewski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg Matlashewski more than expected).

Fields of papers citing papers by Greg Matlashewski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Greg Matlashewski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg Matlashewski. The network helps show where Greg Matlashewski may publish in the future.

Co-authorship network of co-authors of Greg Matlashewski

This figure shows the co-authorship network connecting the top 25 collaborators of Greg Matlashewski. A scholar is included among the top collaborators of Greg Matlashewski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Greg Matlashewski. Greg Matlashewski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Wen‐Wei & Greg Matlashewski. (2024). Evidence for gene essentiality in Leishmania using CRISPR. PLoS ONE. 19(12). e0316331–e0316331. 1 indexed citations

Dey, Ranadhir, Kamaleshwar P. Singh, Patrick Lypaczewski, et al.. (2023). Production of leishmanin skin test antigen from Leishmania donovani for future reintroduction in the field. Nature Communications. 14(1). 7028–7028. 8 indexed citations

Volpedo, Greta, Parna Bhattacharya, Shinjiro Hamano, et al.. (2023). Leishmania major centrin knock-out parasites reprogram tryptophan metabolism to induce a pro-inflammatory response. iScience. 26(9). 107593–107593. 4 indexed citations

Volpedo, Greta, Thalia Pacheco‐Fernández, Erin A. Holcomb, et al.. (2022). Centrin-deficient Leishmania mexicana confers protection against New World cutaneous leishmaniasis. npj Vaccines. 7(1). 32–32. 21 indexed citations

Lypaczewski, Patrick, et al.. (2022). An intraspecies Leishmania donovani hybrid from the Indian subcontinent is associated with an atypical phenotype of cutaneous disease. iScience. 25(2). 103802–103802. 20 indexed citations

Zhang, Wen‐Wei, et al.. (2022). Reconstitution of Mycobacterium marinum Nonhomologous DNA End Joining Pathway in Leishmania. mSphere. 7(3). e0015622–e0015622. 6 indexed citations

Lypaczewski, Patrick, et al.. (2022). Investigating the Leishmania donovani sacp Gene and Its Role in Macrophage Infection and Survival in Mice. Tropical Medicine and Infectious Disease. 7(11). 384–384. 3 indexed citations

Karmakar, Subir, Greta Volpedo, Wen‐Wei Zhang, et al.. (2022). Centrin-deficient Leishmania mexicana confers protection against Old World visceral leishmaniasis. npj Vaccines. 7(1). 157–157. 12 indexed citations

Ashwin, Helen, Jovana Sádlová, Barbora Vojtková, et al.. (2021). Characterization of a new Leishmania major strain for use in a controlled human infection model. Nature Communications. 12(1). 215–215. 34 indexed citations

10.

Lypaczewski, Patrick, Wen‐Wei Zhang, & Greg Matlashewski. (2021). Evidence that a naturally occurring single nucleotide polymorphism in the RagC gene of Leishmania donovani contributes to reduced virulence. PLoS neglected tropical diseases. 15(2). e0009079–e0009079. 9 indexed citations

11.

Lypaczewski, Patrick, et al.. (2021). A review of the leishmanin skin test: A neglected test for a neglected disease. PLoS neglected tropical diseases. 15(7). e0009531–e0009531. 26 indexed citations

12.

Mou, Zhirong, Edgard M. Mejia, Wen‐Wei Zhang, et al.. (2021). The Phosphoenolpyruvate Carboxykinase Is a Key Metabolic Enzyme and Critical Virulence Factor of Leishmania major. The Journal of Immunology. 206(5). 1013–1026. 3 indexed citations

13.

Mondal, Dinesh, Md. Sakhawat Hossain, Debashis Ghosh, et al.. (2016). Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: an open clinical trial and case–control study protocol. BMJ Open. 6(5). e010050–e010050. 12 indexed citations

14.

Zhang, Wen‐Wei & Greg Matlashewski. (2015). CRISPR-Cas9-Mediated Genome Editing in Leishmania donovani. mBio. 6(4). e00861–e00861. 134 indexed citations

15.

Miranda‐Verástegui, César, Gianfranco Tulliano, Theresa W. Gyorkos, et al.. (2009). First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent Antimony. LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas). 1 indexed citations

16.

Buates, Sureemas & Greg Matlashewski. (2001). General Suppression of Macrophage Gene Expression During Leishmania donovani Infection. The Journal of Immunology. 166(5). 3416–3422. 102 indexed citations

17.

Thomas, Miranda, Ann Kalita, Sylvie Labrecque, et al.. (1999). Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically. Molecular and Cellular Biology. 19(2). 1092–1100. 603 indexed citations breakdown →

18.

Buates, Sureemas & Greg Matlashewski. (1999). Treatment of Experimental Leishmaniasis with the Immunomodulators Imiquimod and S‐28463: Efficacy and Mode of Action. The Journal of Infectious Diseases. 179(6). 1485–1494. 139 indexed citations

19.

Charest, Hugues, Wen‐Wei Zhang, & Greg Matlashewski. (1996). The Developmental Expression of A2 Amastigote-specific Genes Is Post-transcriptionally Mediated and Involves Elements Located in the 3′-Untranslated Region. Journal of Biological Chemistry. 271(29). 17081–17090. 121 indexed citations

20.

Matlashewski, Greg, Simon Tuck, D. Pim, et al.. (1987). Primary Structure Polymorphism at Amino Acid Residue 72 of Human p53. Molecular and Cellular Biology. 7(2). 961–963. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact